三支病变或左主干病变患者血运重建完全性与10年全因死亡的SYNTAXES研究
SYNTAXES研究评估了三支病变或左主干病变患者中不完全血运重建(IR)与完全血运重建(CR)对10年全因死亡的影响。结果显示,PCI后IR常见(56.6% vs CABG 36.8%),且IR程度与10年死亡率相关;PCI合并IR者10年全因死亡风险显著高于CABG合并CR者(33.5% vs 23.7%,校正HR 1.48,95%CI 1.15-1.91)。若PCI难以达到完全或近完全血运重建(rSS≤8),应考虑CABG。
要点
- PCI后不完全血运重建更常见,且与10年全因死亡风险增加相关。
- PCI合并IR者10年全因死亡风险显著高于CABG合并CR者(校正HR 1.48)。
- PCI后rSS>8者10年全因死亡风险显著高于完全血运重建者(校正HR 3.40)。
核心结论
- PCI后不完全血运重建常见,且不完全程度与10年全因死亡风险相关。
- 若三支病变患者PCI难以达到完全或近完全血运重建(rSS≤8),应考虑CABG。
研究设计与样本
- SYNTAX Extended Survival研究评估了原SYNTAX试验患者随访至10年的生存状态。
- 本亚组研究比较了CABG完全血运重建组与CABG不完全血运重建、PCI完全血运重建和PCI不完全血运重建组。
- 在PCI队列中,使用残余SYNTAX评分(rSS)量化不完全血运重建程度,rSS=0提示完全血运重建,rSS>0提示不完全血运重建。
主要发现
- 不完全血运重建在PCI患者中比CABG更常见(56.6% vs 36.8%),且在PCI组(58.5% vs 53.8%)和CABG组(42.8% vs 27.5%)中三支病变患者均比左主干病变患者更常见。
- PCI完全血运重建者与CABG(伴或不伴不完全血运重建)者10年全因死亡无显著差异(PCI CR 22.2% vs CABG IR 24.3% vs CABG CR 23.8%)。
- PCI不完全血运重建者10年全因死亡风险显著高于CABG完全血运重建者(33.5% vs 23.7%;校正HR 1.48,95%CI 1.15-1.91)。
- PCI患者按rSS分层,rSS≤8者10年全因死亡与完全血运重建者无显著差异(rSS=0为22.2%,rSS>0-4为23.9%,rSS>4-8为28.9%),而rSS>8者10年全因死亡风险显著高于完全血运重建者(50.1% vs 22.2%;校正HR 3.40,95%CI 2.13-5.43)。
关键数值与推荐
- rSS=0提示完全血运重建,rSS>0提示不完全血运重建。
- PCI不完全血运重建者10年全因死亡风险显著高于CABG完全血运重建者(校正HR 1.48,95%CI 1.15-1.91)。
- PCI后rSS>8者10年全因死亡风险显著高于完全血运重建者(校正HR 3.40,95%CI 2.13-5.43)。
- 若三支病变患者PCI难以达到完全或近完全血运重建(rSS≤8),应考虑CABG。
临床怎么用
- 对三支病变或左主干病变患者行PCI时,应评估能否达到完全或近完全血运重建(rSS≤8)。
- 若PCI难以达到完全或近完全血运重建,应优先考虑CABG。
- PCI后应计算残余SYNTAX评分以量化不完全血运重建程度,辅助判断长期风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ten-year all-cause death according to incomplete (IR) versus complete revascularization (CR) has not been fully investigated in patients with 3-vessel disease and left main coronary artery disease undergoing percutaneous coronary intervention (PCI) versus coronary artery bypass grafting (CABG). METHODS: The SYNTAX Extended Survival study (Synergy Between PCI With TAXUS and Cardiac Surgery: SYNTAX Extended Survival [SYNTAXES]) evaluated vital status up to 10 years in patients who were originally enrolled in the SYNTAX trial. In the present substudy, outcomes of the CABG CR group were compared with the CABG IR, PCI CR, and PCI IR groups. In addition, in the PCI cohort, the residual SYNTAX score (rSS) was used to quantify the extent of IR and to assess its association with fatal late outcome. The rSS of 0 suggests CR, whereas a rSS>0 identifies the degree of IR. RESULTS: IR was more frequently observed in patients with PCI versus CABG (56.6% versus 36.8%) and more common in those with 3-vessel disease than left main coronary artery disease in both the PCI arm (58.5% versus 53.8%) and the CABG arm (42.8% versus 27.5%). Patients undergoing PCI with CR had no significant difference in 10-year all-cause death compared with those undergoing CABG (22.2% for PCI with CR versus 24.3% for CABG with IR versus 23.8% for CABG with CR). In contrast, those with PCI and IR had a significantly higher risk of all-cause death at 10 years compared with CABG and CR (33.5% versus 23.7%; adjusted hazard ratio, 1.48 [95% CI, 1.15-1.91]). When patients with PCI were stratified according to the rSS, those with a rSS≤8 had no significant difference in all-cause death at 10 years as the other terciles (22.2% for rSS=0 versus 23.9% for rSS>0-4 versus 28.9% for rSS>4-8), whereas a rSS>8 had a significantly higher risk of 10-year all-cause death than those undergoing PCI with CR (50.1% versus 22.2%; adjusted hazard ratio, 3.40 [95% CI, 2.13-5.43]). CONCLUSIONS: IR is common after PCI, and the degree of incompleteness was associated with 10-year mortality. If it is unlikely that complete (or nearly complete; rSS<8) revascularization can be achieved with PCI in patients with 3-vessel disease, CABG should be considered. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00114972. URL: https://www.clinicaltrials.gov; Unique identifier: NCT03417050.
引用
- Takahashi K, Serruys PW, Gao C, et al. Ten-Year All-Cause Death According to Completeness of Revascularization in Patients With Three-Vessel Disease or Left Main Coronary Artery Disease: Insights From the SYNTAX Extended Survival Study. Circulation. 2021. PMID: 34011163. doi:10.1161/CIRCULATIONAHA.120.046289
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。